Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Feb 25

PMID 36831640

Authors

Loick Galland

Nicolas Roussot

Isabelle Desmoulins

Didier Mayeur

Coureche Kaderbhai

Silvia Ilie

Audrey Hennequin

Manon Reda

Juliette Albuisson

Laurent Arnould

Romain Boidot

Caroline Truntzer

Francois Ghiringhelli

Sylvain Ladoire

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized treatment. Thanks to next-generation sequencing (NGS), progress in biomedical technologies, and the use of bioinformatics, it is now possible to identify specific molecular alterations in tumor cells-such as homologous recombination deficiencies (HRD)-enabling us to consider using DNA-damaging agents such as platinum salts or PARP inhibitors. Different approaches currently exist to analyze impairment of the homologous recombination pathway, e.g., the search for specific mutations in homologous recombination repair (HRR) genes, such as /; the use of genomic scars or mutational signatures; or the development of functional tests. Nevertheless, the role and value of these different tests in breast cancer treatment decisions remains to be clarified. In this review, we summarize current knowledge on the clinical utility of genomic tests, evaluating HRR deficiency for treatment decisions in early and metastatic breast cancer.

Citing Articles

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.

Pasto B, Vida R, Dri A, Foffano L, Della Rossa S, Gerratana L Breast. 2024; 79:103859.

PMID: 39708442 PMC: 11872398. DOI: 10.1016/j.breast.2024.103859.

Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database.

Ishigaki K, Tokito Y, Takahara N, Nishio H, Endo G, Fukuda K J Gastroenterol. 2024; 60(2):247-256.

PMID: 39570378 PMC: 11794350. DOI: 10.1007/s00535-024-02173-0.

Development of a prognostic model related to homologous recombination deficiency in glioma based on multiple machine learning.

Gong Z, Zhou D, Shen H, Ma C, Wu D, Hou L Front Immunol. 2024; 15:1452097.

PMID: 39434883 PMC: 11491349. DOI: 10.3389/fimmu.2024.1452097.

Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status.

Laczmanska I, Matkowski R, Supplitt S, Karpinski P, Abrahamowska M, Laczmanski L Breast Cancer Res Treat. 2024; 208(3):501-510.

PMID: 39080120 PMC: 11522089. DOI: 10.1007/s10549-024-07441-4.

Association between homologous recombination deficiency status and carboplatin treatment response in early triple-negative breast cancer.

Wang Z, Lu Y, Han M, Li A, Ruan M, Tong Y Breast Cancer Res Treat. 2024; 208(2):429-440.

PMID: 39048852 PMC: 11457550. DOI: 10.1007/s10549-024-07436-1.

References

Hodgson D, Lai Z, Dearden S, Barrett J, Harrington E, Timms K . Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Ann Oncol. 2021; 32(12):1582-1589. DOI: 10.1016/j.annonc.2021.08.2154. View

Tung N, Arun B, Hacker M, Hofstatter E, Toppmeyer D, Isakoff S . TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol. 2020; 38(14):1539-1548. PMC: 8462533. DOI: 10.1200/JCO.19.03292. View

Drew Y, Mulligan E, Vong W, Thomas H, Kahn S, Kyle S . Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2010; 103(4):334-46. DOI: 10.1093/jnci/djq509. View

Wright W, Shah S, Heyer W . Homologous recombination and the repair of DNA double-strand breaks. J Biol Chem. 2018; 293(27):10524-10535. PMC: 6036207. DOI: 10.1074/jbc.TM118.000372. View

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P . Breast cancer. Nat Rev Dis Primers. 2019; 5(1):66. DOI: 10.1038/s41572-019-0111-2. View

Ladan M, van Gent D, Jager A . Homologous Recombination Deficiency Testing for BRCA-Like Tumors: The Road to Clinical Validation. Cancers (Basel). 2021; 13(5). PMC: 7957671. DOI: 10.3390/cancers13051004. View

Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J . Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing. NPJ Breast Cancer. 2022; 8(1):28. PMC: 8897409. DOI: 10.1038/s41523-022-00395-0. View

Watkins J, Irshad S, Grigoriadis A, Tutt A . Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers. Breast Cancer Res. 2014; 16(3):211. PMC: 4053155. DOI: 10.1186/bcr3670. View

10.

Alba E, Chacon J, Lluch A, Anton A, Estevez L, Cirauqui B . A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study. Breast Cancer Res Treat. 2012; 136(2):487-93. DOI: 10.1007/s10549-012-2100-y. View

11.

Cruz C, Castroviejo-Bermejo M, Gutierrez-Enriquez S, Llop-Guevara A, Ibrahim Y, Gris-Oliver A . RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Ann Oncol. 2018; 29(5):1203-1210. PMC: 5961353. DOI: 10.1093/annonc/mdy099. View

12.

Zhao W, Steinfeld J, Liang F, Chen X, Maranon D, Ma C . BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing. Nature. 2017; 550(7676):360-365. PMC: 5800781. DOI: 10.1038/nature24060. View

13.

Gou R, Dong H, Lin B . Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy. Life Sci. 2020; 261:118434. DOI: 10.1016/j.lfs.2020.118434. View

14.

Fasching P, Link T, Hauke J, Seither F, Jackisch C, Klare P . Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann Oncol. 2020; 32(1):49-57. DOI: 10.1016/j.annonc.2020.10.471. View

15.

Morganella S, Alexandrov L, Glodzik D, Zou X, Davies H, Staaf J . The topography of mutational processes in breast cancer genomes. Nat Commun. 2016; 7:11383. PMC: 5001788. DOI: 10.1038/ncomms11383. View

16.

Meijer T, Verkaik N, Sieuwerts A, van Riet J, Naipal K, van Deurzen C . Functional Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects. Clin Cancer Res. 2018; 24(24):6277-6287. DOI: 10.1158/1078-0432.CCR-18-0063. View

17.

Waks A, Cohen O, Kochupurakkal B, Kim D, Dunn C, Buendia Buendia J . Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020; 31(5):590-598. PMC: 7946408. DOI: 10.1016/j.annonc.2020.02.008. View

18.

Loibl S, Weber K, Timms K, Elkin E, Hahnen E, Fasching P . Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol. 2018; 29(12):2341-2347. DOI: 10.1093/annonc/mdy460. View

19.

Caramelo O, Silva C, Caramelo F, Frutuoso C, Almeida-Santos T . The effect of neoadjuvant platinum-based chemotherapy in mutated triple negative breast cancers -systematic review and meta-analysis. Hered Cancer Clin Pract. 2019; 17:11. PMC: 6434625. DOI: 10.1186/s13053-019-0111-y. View

20.

Tutt A, Robson M, Garber J, Domchek S, Audeh M, Weitzel J . Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):235-44. DOI: 10.1016/S0140-6736(10)60892-6. View